McKesson ’s Board of Directors Elects James H. Hinton and Kathleen Wilson-Thompson as New Directors
IRVING, Texas, Jan. 18, 2022 – McKesson Corporation (NYSE: MCK) announced today that the McKesson board of directors elected James H. Hinton and Kathleen Wilson-Thompson as directors on Jan. 13, 2022. McKesson expects that the board will appoint Hinton to the Compliance Committee and Governance Comm... (Source: McKesson News)
Source: McKesson News - January 18, 2022 Category: Information Technology Source Type: news
McKesson Corporation Announces Third Quarter Fiscal 2022 Earnings Release Date and Participation in January Conference
IRVING, Texas, December 29, 2021 — McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2022 financial results after market close on Wednesday, February 2, 2022. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its... (Source: McKesson News)
Source: McKesson News - December 29, 2021 Category: Information Technology Source Type: news
Distributors Announce Extension of Opioid Settlement Sign-On Period, Participation of New Mexico
CONSHOHOCKEN, Pa.& DUBLIN, Ohio& IRVING, Texas — AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that the deadline for political subdivisions in participating states to join the previously announced proposed opioid settlement agreement has been ex... (Source: McKesson News)
Source: McKesson News - December 22, 2021 Category: Information Technology Source Type: news
TARPEYO & lt;sup & gt;TM & lt;/sup & gt; (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYOTM (budesonide) delayed release capsules to reduce proteinuria in adults... (Source: McKesson News)
Source: McKesson News - December 22, 2021 Category: Information Technology Source Type: news
TARPEYO < sup > TM < /sup > (budesonide) delayed release capsules, FDA Approved to Reduce Proteinuria in IgA Nephropathy, Available Exclusively at Biologics by McKesson
CARY, N.C., Dec. 22, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Calliditas Therapeutics as the exclusive specialty pharmacy provider for TARPEYOTM (budesonide) delayed release capsules to reduce proteinuria in adults ... (Source: McKesson News)
Source: McKesson News - December 21, 2021 Category: Information Technology Source Type: news
McKesson Corporation Enters Agreement to Sell its Austrian Business to Quadrifolia Management GmbH
IRVING, Texas, 20 December, 2021 - McKesson Corporation (NYSE: MCK) today announced that it has entered into an agreement to sell its Austrian business to Quadrifolia Management GmbH ( “Quadrifolia”). The transaction includes the sale of McKesson Austria’s Herba Chemosan Apotheker-AG, together with S... (Source: McKesson News)
Source: McKesson News - December 20, 2021 Category: Information Technology Source Type: news
US Oncology Research, The US Oncology Network and Ontada Announce Data Presentations across Areas of Critical Need at 2021 American Society of Hematology Annual Meeting and Exposition
THE WOODLANDS, Texas, Dec. 9, 2021 — Investigators from US Oncology Research, The US Oncology Network (The Network), and OntadaTM will share results from more than 30 studies exploring areas such as diffuse large B cell lymphoma, non-Hodgkin lymphoma, multiple myeloma and hematological adverse even... (Source: McKesson News)
Source: McKesson News - December 9, 2021 Category: Information Technology Source Type: news
McKesson Investor Day to Highlight Progress Against Growth Strategies and Long-Term Financial Targets
IRVING, Texas – December 8, 2021 -- McKesson Corporation (NYSE: MCK) today will host an Investor Day beginning at 1:00 p.m. ET, where executive leadership will provide an overview of the company’s progress towards its goal of delivering sustainable growth and details around the company’s long-term f... (Source: McKesson News)
Source: McKesson News - December 8, 2021 Category: Information Technology Source Type: news
BESREMi (ropeginterferon alfa-2b-njft), FDA Approved for Treatment of Polycythemia Vera, Available at Biologics by McKesson
CARY, N.C., Dec. 6, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by PharmaEssentia USA Corporation as a specialty pharmacy provider for BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia... (Source: McKesson News)
Source: McKesson News - December 6, 2021 Category: Information Technology Source Type: news
Newly Approved LIVTENCITY (maribavir) Now Available at Biologics by McKesson
CARY, N.C., Dec. 3, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Takeda Pharmaceuticals as a specialty pharmacy provider for LIVTENCITYTM (maribavir), indicated for the treatment of adults and pediatric patients (12 ye... (Source: McKesson News)
Source: McKesson News - December 3, 2021 Category: Information Technology Source Type: news
McKesson to Host Investor Day on December 8, 2021
IRVING, Texas – December 1, 2021—McKesson Corporation (NYSE: MCK) will host an Investor Day on Wednesday, December 8, 2021 from 1:00 PM to 4:00 PM ET in New York City. The meeting will feature presentations by McKesson’s leadership team and a live Q&A session with chief executive officer Brian Tyler... (Source: McKesson News)
Source: McKesson News - December 1, 2021 Category: Information Technology Source Type: news
Walgreens Boots Alliance Acquires Remaining Stake in German GEHE-Alliance Healthcare Joint Venture From McKesson
DEERFIELD, Ill., and IRVING, Texas, Nov. 30, 2021 —Walgreens Boots Alliance (Nasdaq: WBA) and McKesson Corporation (NYSE: MCK) have today reached an agreement for WBA to acquire the remaining 30% share of their GEHE Pharma Handel (GEHE) and Alliance Healthcare Deutschland (AHD) joint venture. Followi... (Source: McKesson News)
Source: McKesson News - November 30, 2021 Category: Information Technology Source Type: news
New Metrics Show The US Oncology Network Practices Leading the Way in Value-Based Care
THE WOODLANDS, TEXAS, Nov. 16, 2021 — The Centers for Medicare& Medicaid Innovation (CMMI) recently released results for the 8th Performance Period (PP8) of the Oncology Care Model (OCM), and practices in The US Oncology Network (The Network) participating in the program achieved high marks on qual... (Source: McKesson News)
Source: McKesson News - November 16, 2021 Category: Information Technology Source Type: news
McKesson Opens State-of-the-Art Distribution Center in Michigan
IRVING, Texas, Nov. 4, 2021 — McKesson Corporation has opened a new pharmaceutical distribution center in Holt, Mich., seven miles south of Lansing. The facility will add more than 80 full-time jobs to the region, including day and night shifts offering competitive pay and benefits. (Source: McKesson News)
Source: McKesson News - November 4, 2021 Category: Information Technology Source Type: news
EXKIVITY (mobocertinib), First and Only FDA Approved Oral Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer, Available at Biologics by McKesson
CARY, N.C., Nov. 3, 2021 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Takeda Pharmaceutical Limited Company as a specialty pharmacy provider for EXKIVITYTM (mobocertinib) for the treatment of adult patients with locally adv... (Source: McKesson News)
Source: McKesson News - November 3, 2021 Category: Information Technology Source Type: news
